Reducing Risk And Timelines In Cell Line Development

Pharmaceutical companies developing biologics often face the critical challenge of selecting a stable cell line capable of consistently producing high-quality therapeutic proteins. Traditionally, this process takes more than 12 weeks, involving extensive stability studies to ensure the chosen clone maintains consistent productivity over time. However, this lengthy timeline exposes the project to potential risks, as instabilities in the clone may only become apparent at the end of the testing period, potentially delaying production and increasing costs.

Recognizing the inefficiencies of this traditional approach, AGC Biologics set out to find a solution that could identify unstable clones earlier in the process, enabling faster and more reliable clone selection. By doing so, AGC Biologics aims to significantly reduce the time and resources spent on cell line development (CLD), while increasing the chances of selecting a stable, high-producing clone, ultimately accelerating the production of life-saving biologic therapies.